Bli medlem
Bli medlem

Du är här

2016-04-05

AddLife: AddLife publishes prospectus supplement

On the 30 March 2016, the Board of Directors of AddLife AB (publ)
("AddLife") resolved on the terms and conditions of the share issue
with preferential rights for existing shareholders in AddLife (the
"Issue"). The terms and conditions were published through a press
release the same day. The decision regarding the terms and conditions
of the Issue, as well as the acquisitions of V-Tech AB and Esthe-Tech
AB and that AddLife signed an agreement to represent Leica Biosystems
in Sweden and Denmark, which have been published through press
releases on 17 March 2016 and 4 April 2016, respectively, required
that a prospectus supplement was prepared. The prospectus supplement
has now been approved and registered by the Swedish Financial
Supervisory Authority. The prospectus supplement is available on the
company's website, www.add.life, as well as on Handelsbanken's
website, www.handelsbanken.se/investeringserbjudande.

Handelsbanken Capital Markets acts as financial adviser and
Advokatfirman Delphi acts as legal adviser in connection with the
Issue.

Stockholm, April 5, 2016

AddLife AB (publ)

For further information, please contact:

Kristina Willgård, CEO, kristina.willgard@add.life, +46 70 510 12 23

Martin Almgren, CFO, martin.almgren@add.life, +46 70 228 15 45

IMPORTANT INFORMATION

The information in this press release shall not constitute an offer to
acquire, subscribe for or otherwise trade in shares or other
securities in AddLife. No action has been taken and measures will not
be taken to permit a public offering in any jurisdictions other than
Sweden. Invitation to the persons concerned to subscribe for shares
is only made through the prospectus which AddLife published on 15
March 2016.

The information in this press release may not be released, published
or distributed, directly or indirectly, in or into the United States
(including its territories and provinces, every state in the United
States and the District of Columbia), Canada, Australia, Japan, Hong
Kong, New Zeeland, Switzerland, Singapore, South Africa or any other
jurisdiction in which such action is subject to legal restrictions or
would require other measures than those required by Swedish law.
Actions in violation of these restrictions may constitute a violation
of applicable securities laws.

No shares or other securities have or will be registered under the
United States Securities Act of 1933 or the securities legislation in
any state or other jurisdiction in the United States and may not be
offered, subscribed, sold or transferred, directly or indirectly,
within the United States.

AddLife is an independent player in the Life Science sector, offering
high-quality products, services and advice to the private and public
sectors, above all in the Nordic region. AddLife has about 425
employees in some 25 subsidiaries that operate under their own
brands. The Group has annual sales of about SEK 1.7 billion.
Addlife's shares are listed on Nasdaq Stockholm.

This information is disclosed in accordance with the Swedish
Securities Markets Act, the Swedish Financial Instruments Trading Act
and/or the regulations of Nasdaq Stockholm. The information was
provided for publication at 17:15 PM on April 5 2016.

-----------------------------------------------------------
http://news.cision.com/addlife/r/addlife-publishes-prospectus-supplement...
http://mb.cision.com/Main/13919/9949719/496875.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.